^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Chronic lymphocytic leukemia/Small lymphocytic lymphoma: Suggested treatment regimens...CLL/SLL with del(17p)/TP53 mutation…relapsed/refractory therapy…other recommended regimens…lenalidomide ± rituximab
